

## Expanded View Figures

### Figure EV1. LINC00839 promotes the proliferation, migration, invasion, and EMT of CRC cells.

- A Knockdown of LINC00839 was confirmed in SW620 and HCT116 cells by qPCR (mean  $\pm$  SD, Student's *t*-test, *n* = 3 technical replicates).
- B, C Cell proliferation was measured by CCK8 assay in LINC00839-knockdown SW620 and HCT116 cells (mean  $\pm$  SD, ANOVA, *n* = 3 biological replicates).
- D Colony formation was assessed in LINC00839-knockdown SW620 and HCT116 cells.
- E Wound-healing assay was performed with LINC00839-knockdown cells and control cells. Scale bars, 100  $\mu$ m.
- F Matrigel invasion assay was performed with LINC00839-knockdown HCT116 and SW620 cells. Scale bars, 100  $\mu$ m.
- G The CDX model revealed the effect of LINC00839 on tumor growth. Representative image of tumors harvested from the mouse model (left panel), quantitative analysis of tumor weight and tumor volume (medium panel), and representative images and quantification of IHC staining of Ki-67 in tumor tissues (left panel; *n* = 6 for each cohort; the results are presented as the mean  $\pm$  SD and were analyzed by Student's *t*-test (medium and right panel) and ANOVA (left panel)). Scale bars, 100  $\mu$ m (*n* = 6 biological replicates).
- H Cells overexpressing LINC00839 exhibited EMT-like cell morphology: most cells lost their epithelial characteristics and exhibited a spindle-shaped and fibroblast-like morphology. Scale bars, 10  $\mu$ m.
- I GSEA showed the enrichment of epithelial–mesenchymal transition (EMT) signatures in the high HCT116 and SW620 cells expression group (TCGA cohort).
- J IF staining of E-cadherin and Vimentin in LINC00839-overexpressing and LINC00839-knockdown cells. Scale bars, 10  $\mu$ m.
- K Epithelial and mesenchymal marker expression in LINC00839-overexpressing and LINC00839-knockdown cells was measured by WB.
- L Representative images of IHC staining of Vimentin and E-cadherin in tumors from the orthotopic implantation model. Scale bars, 200  $\mu$ m.

Data information: In (D–F), the data are presented as the mean  $\pm$  SD and were analyzed by Student's *t*-test, *n* = 3 biological replicates. Across experiments, the *P*-values are as follows: ns = not significant, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001.

Source data are available online for this figure.




Figure EV1.

**Figure EV2. LINC00839 interacts with the Ruvb1/Tip60 complex to promote OXPHOS and mitochondrial biogenesis.**

- A Ruvb1 was identified by LC-MS.
- B The peak diagram of the centroid structure of LINC00839 was predicted by RNAfold.
- C Pattern of the structure of LINC00839 and Ruvb1 and their binding.
- D RNA pull-down and WB assays were performed to confirm the specific interaction between some large multiprotein complexes and LINC00839. Dot blot of RNA-protein binding samples indicating that equal amounts of RNA were used in the assay.
- E The Ruvb1 knockdown efficiency was confirmed by WB.
- F GO enrichment analysis of the DEGs identified in the RNA-seq.
- G Glucose intake by LINC00839-overexpressing cells and LINC00839-KD cells was determined.
- H Lactate secretion by LINC00839-overexpressing cells and LINC00839-KD cells was measured.
- I, J The number of mitochondria in LINC00839-knockdown cells and LINC00839-overexpressing cells as confirmed by TEM. Scale bars, 500 nm.

Data information: In (G–J), the data are presented as the mean  $\pm$  SD and were analyzed by Student's *t*-test, *n* = 3 biological replicates. Across experiments, the *P*-values are as follows: ns = not significant, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001.

Source data are available online for this figure.




Figure EV2.

**Figure EV3. LINC00839 mediates the acetylation of the NRF1 promoter by the Ruvb1/Tip60 complex to regulate OXPHOS, mitochondrial biogenesis, and CRC progression.**

- A The pattern of 10 NRF1 promoter fragments (upper panel) and ChIP-seq uniform peaks in the NRF1 promoter region was analyzed by ENCODE projects and visualized by UCSC Genome Browser (bottom panel).
- B–E The enrichment of the NRF1 promoter (P1–P10) by Tip60 (B), Ruvb1 (C), H4K12ac (D), and H3K14ac (E) antibodies in LINC00839-overexpressing and control LoVo cells as determined by CHIP assay. Normal IgG was used as a negative control.
- F, G ATP levels and NAD/NADH ratios in SW480 and LoVo cells were measured.
- H Expression of genes related to mitochondrial biogenesis and EMT in SW480 and LoVo cells as determined by WB.
- I The number of mitochondria in SW480 and LoVo cells was confirmed by TEM. Scale bars, 500 nm.
- J Invasion of SW480 and LoVo cells was assessed by Matrigel invasion assay. Scale bars, 100  $\mu$ m.

Data information: In (B–G), the data are presented as the mean  $\pm$  SD and were analyzed by Student's *t*-test, *n* = 3 technical replicates. In (I, J), the data are presented as the mean  $\pm$  SD and were analyzed by Student's *t*-test, *n* = 3 biological replicates. Across experiments, the *P*-values are as follows: ns = not significant, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001.

Source data are available online for this figure.





Figure EV3.



**Figure EV4. LINC00839 promotes OXPHOS, mitochondrial biogenesis, and CRC invasion through Ruvb1/Tip60-NRF1 signaling.**

A The NRF1 knockdown efficiency was confirmed by WB.

B The number of mitochondria in SW480 and LoVo cells was confirmed by TEM. Scale bars, 500 nm.

C, D ATP levels and NAD/NADH ratios in SW480 and LoVo cells were determined.

E The number of mitochondria in SW480 and LoVo cells was confirmed by TEM. Scale bars, 500 nm.


F Invasion of SW480 and LoVo cells was determined by Matrigel invasion assay. Scale bars, 100 μm.

G Expression of genes related to mitochondrial biogenesis and EMT markers in SW480 and LoVo cells as determined by WB.

Data information: In (B, E, and F), the data are presented as the mean ± SD and were analyzed by Student's *t*-test, *n* = 3 biological replicates. In (C and D), the data are presented as the mean ± SD and were analyzed by Student's *t*-test, *n* = 3 technical replicates. Across experiments, the *P*-values are as follows: ns = not significant,

\**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001.

Source data are available online for this figure.



**Figure EV5. LINC00839 promotes CRC progression through Ruvb1/Tip60-NRF1-mediated OXPHOS.**

A Invasion of LINC00839-overexpressing cells treated with FCCP and MTH was determined by Matrigel invasion assay. Scale bar, 100  $\mu$ m.

B EMT marker expression levels in LINC00839-overexpressing cells treated with FCCP and MTH were measured by WB.

C Invasion of LINC00839-knockdown cells in which NRF1 was overexpressed and to which FCCP and MTH were added was measured by Matrigel invasion assay. Scale bar, 100  $\mu$ m.

D EMT marker expression levels in LINC00839-knockdown cells in which NRF1 was overexpressed and to which FCCP and MTH were added were measured by WB.

E The correlation between the expression of LINC00839 and Ruvb1 in the CRC cohort ( $n = 120$ , Pearson).

F The correlation between the expression of LINC00839 and Tip60 in the CRC cohort ( $n = 120$ , Pearson).

G The expression levels of NRF1 in patients with early-stage (stage I and II) and advanced-stage (stage III and IV) disease.

H Expression of NRF1 in nonmetastatic CRC patients (nmCRC) and metastatic CRC patients (mCRC).

Data information: In (A and C) the data are presented as the mean  $\pm$  SD and were analyzed by Student's *t*-test,  $n = 3$  biological replicates. In (G), the middle lines represent the median, and the upper and lower lines represent the upper and lower quartiles. In (H), the data are presented as the mean  $\pm$  SD and were analyzed by Student's *t*-test. Across experiments, the *P*-values are as follows: ns = not significant, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001.

Source data are available online for this figure.